Endometriosis is an estrogen-driven, inflammatory disorder affecting ~10% of menstruators, causing severe pain. Current treatments that reduce estrogen or inflammation have inconsistent efficacy and poor tolerability. Therapies identified via drug-repositioning …
Traditional behavioral finance-which examines how cognitive biases, emotions, and context shape economic decision-making- often assumes cognitive stability, rationality, and consistent risk evaluation, based largely on male-dominated samples. Emerging evidence from …
Endometriosis is a chronic gynecological disorder characterized by persistent pain and impaired quality of life, with limited effective treatment options. Emerging evidence indicates that cannabinoids may provide analgesic and symptom-relieving …
Objectives. The aim of the study was to develop a diagnostic method for estrogen hypersensitivity syndrome in proliferative benign diseases of the female reproductive system. Using the example of endometriosis, …
Epithelial ovarian cancer is not a single disease but a group of biologically distinct malignancies that include serous (high-grade and low-grade), endometrioid, clear cell, and mucinous carcinomas, along with other …
Low-level laser therapy (LLLT; ≤ 0.5 W) is guideline-recommended in the United States for shallow-tissue oral mucositis and other superficial pathologies but has generally failed in trials for deeper tissue …
Background: Cerebral endometriosis is an exceptionally rare manifestation of extrapelvic endometriosis and remains a diagnostic challenge because its clinical and imaging features may mimic more common neurological, inflammatory, vascular, or …
Endometriosis causes pelvic pain, dysmenorrhea (DYS), dyspareunia, and fertility issues. Linustedastat (OG-6219) is an oral, selective inhibitor of 17β-hydroxysteroid dehydrogenase type 1 (HSD17β1), an enzyme involved in local estradiol biosynthesis. …
This study utilized 1990-2019 data from the Global Burden of Disease (GBD) 2019 study to comprehensively evaluate global and regional temporal trends of endometriosis burden.
Relugolix is an oral, non-peptide gonadotropin-releasing hormone receptor antagonist administered as once-daily combination therapy (relugolix-CT; 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate) to reduce endometriosis symptoms while …